|
|
Volumn 162, Issue 6, 2015, Pages 1202-1205
|
|
Checkpoints
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CANCER VACCINE;
CD28 ANTIGEN;
CYTOTOXIC T LYMPHOCYTE ANTIGEN 4;
CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY;
IPILIMUMAB;
T LYMPHOCYTE RECEPTOR;
MONOCLONAL ANTIBODY;
ANTIGEN PRESENTING CELL;
CANCER IMMUNIZATION;
CANCER IMMUNOTHERAPY;
CANCER PATIENT;
CANCER RADIOTHERAPY;
CANCER SURVIVAL;
HUMAN;
IMMUNOLOGIST;
MALIGNANT NEOPLASTIC DISEASE;
METASTATIC MELANOMA;
MONOTHERAPY;
NONHUMAN;
OVERALL SURVIVAL;
PRIORITY JOURNAL;
REGULATORY MECHANISM;
REVIEW;
SCIENTIST;
T LYMPHOCYTE ACTIVATION;
TUMOR REGRESSION;
TUMOR REJECTION;
ANIMAL;
ANTAGONISTS AND INHIBITORS;
ART;
CLINICAL TRIAL (TOPIC);
HISTORY;
IMMUNOLOGY;
IMMUNOTHERAPY;
LYMPHOCYTE ACTIVATION;
NEOPLASMS;
T LYMPHOCYTE;
UNITED STATES;
ANIMALS;
ANTIBODIES, MONOCLONAL;
CLINICAL TRIALS AS TOPIC;
CTLA-4 ANTIGEN;
HISTORY, 20TH CENTURY;
HISTORY, 21ST CENTURY;
HUMANS;
IMMUNOTHERAPY;
LYMPHOCYTE ACTIVATION;
NEOPLASMS;
T-LYMPHOCYTES;
UNITED STATES;
|
|
EID: 84941344233
PISSN: 00928674
EISSN: 10974172
Source Type: Journal
DOI: 10.1016/j.cell.2015.08.047 Document Type: Note |
|
Times cited : (28)
|
|
References (0)
|
